TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed study drug treatment in parent study (VX19-445-116, NCT04353817), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the treatment period in the parent study~Key Exclusion Criteria:~* History of study drug intolerance in the parent study~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Participants 6 to less than \<12 year of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women histologically diagnosed with carcinoma of the breast~2. Women with non-palpable malignant lesions, requiring image guided localization.~3. Undergoing lumpectomy (partial mastectomy) procedure.~4. Age 18 years or more~5. Signed ICF~Exclusion Criteria:~1. Multicentric disease (histologically diagnosed cancer in two different quadrants of the breast)~2. Bilateral disease (diagnosed cancer in both breasts)~3. Neoadjuvant systemic therapy~4. Previous radiation in the operated breast~5. Prior surgical procedure in the same breast~6. Implants in the operated breast~7. Pregnancy~8. Lactation~9. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SOC (Type: ACTIVE_COMPARATOR): Standard of Care arm - standard of care lumpectomy procedure
- Device + SOC (Type: EXPERIMENTAL): Use of the device in addition to the standard of care lumpectomy procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Erythromycin Before Endoscopy in Patients With Variceal Bleeding: A Randomized, Double-Blind Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with liver cirrhosis or stigmata of chronic liver disease presenting with hematemesis and or melena within previous 12 hours with~* Age \>18 years~* Informed consent~* Hemodynamically stable patient at the time of endoscopy after resuscitation.~Exclusion Criteria:~* Known allergy to erythromycin~* Prior gastric lavage on admission~* Current use of antiarrhythmic drugs~* Prior gastric surgery~* Previous history of cardiac arrhythmias~* Concomitant use of antihistaminic drugs with possible drug interactions with erythromycin~* Prior use of other prokinetic agents~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erythromycin (Type: ACTIVE_COMPARATOR): The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
- Placebo Group endoscopic therapy (Type: NO_INTERVENTION): Endoscopic therapy of variceal bleeding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Diagnosed with type 2 diabetes mellitus~* HbA1c 7.1 to 11%, inclusive, at screening~* Fasting plasma glucose \<280 mg/dL (15.5 mmol/L)~* Body mass index (BMI) \<=45 kg/m2, inclusive, at screening~* Treated with diet and exercise or a stable regimen of metformin, sulfonylurea, pioglitazone or any 2 of these agents~Exclusion Criteria:~* History of pancreatitis or triglycerides \>=500 mg/dL~* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either~* Active cardiovascular disease~* Presence of congestive heart failure~* Liver disease~* History of severe gastrointestinal diseases~* Repeated severe hypoglycemia within the last 6 months~* Any previous use of exenatide or other glucagon-like peptide-1 (GLP-1 ) analog~* Dipeptidyl peptidase-4 (DPP-4) inhibitor use in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide once weekly suspension (Type: EXPERIMENTAL): Exenatide suspension 2 mg weekly subcutaneous injection
- Exenatide twice daily (BID) (Type: ACTIVE_COMPARATOR): Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* the patient who undergoing elective TURP for benign prostatic hypertrophy under spinal anesthesia~Exclusion Criteria:~* Past history of spine surgery~* infection focus at back~* coagulopathy~* hypersensitivity to local anaesthetics or DMT~* mental disturbance~* neurological disease

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DXM-bupivacaine (Type: EXPERIMENTAL): None
- saline-bupivacaine (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infant 6-11 week of age~* Infant born after 37-42 week of pregnancy~* Infant weighting more than 2.5 kg at birth~* Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form~* Parents commit themselves to comply with the indication of the investigator and with the schedule of the trial~* Mother at least graduate from elementary school~* Received Hepatitis B vaccine (Bio Farma) at birth~Exclusion Criteria:~* Child concomitantly enroll or schedule to be enroll in another trial~* Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature \>=37.5 Celsius on Day 0)~* Known history of allergy to any component of the vaccine component (e.g.formaldehyde)~* History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular injection~* Known history of congenital or acquired immunodeficiency (including HIV infection)~* Child who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulin, blood derived product or long term corticotherapy (\>2 weeks)~* Other vaccination within the 1 month prior to inclusion with the exception of BCG and poliomyelitis~* Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objective~* Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B infection

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 11 Weeks
- Healthy Volunteers: t

Study Arms:
- DTP/HB/Hib Vaccine (Batch: A) (Type: EXPERIMENTAL): Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
- DTP/HB/Hib vaccine (Batch: B) (Type: EXPERIMENTAL): Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
- DTP/HB/Hib vaccine (Batch: C) (Type: EXPERIMENTAL): Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: So-Lo-Mo Intervention Applied to the Smoking Cessation Process

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking population attending to the Smoking Cessation Unit of Virgen del Rocío University Hospital.~* Subjects \>18 years old who want to give up smoking.~* Android-based smart phone availability.~* Ability to interact with the smart phone.~* To sign an Informed Consent Form.~Exclusion Criteria:~* Subjects had some previous adverse effects related to the pharmacological treatment included in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.~Prescribed treatments:~* Bupropion pills + Psychological advice~* Varenicline pills + Psychological advice
- Intervention (Type: EXPERIMENTAL): Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.~Prescribed treatments:~* Bupropion pills + Psychological advice + So-Lo-Mo~* Varenicline pills + Psychological advice + So-Lo-Mo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical diagnosis of idiopathic or genetic Cervical Dystonia~Exclusion Criteria:~* Current treatment with botulinum toxin of any type for any other indication (including aesthetic indications) and for any body region during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Xeomin® Short Flex (Type: ACTIVE_COMPARATOR): short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
- Xeomin® Long Flex (Type: ACTIVE_COMPARATOR): long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multifactorial Approach to Emergent Cerclage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* GA 16+0 to 23+6 weeks~* Singleton gestation~* Presence of cervical dilation as diagnosed on digital examination~* Intact membranes~Exclusion Criteria:~* Age \<18 years~* Allergy to NSAIDs~* Renal disease~* Allergy to penicillins AND clindamycin~* Currently on antibiotics or indomethacin for any reason~* HIV positive~* Pregnancies complicated by fetal congenital anomalies~* Preterm premature rupture of membranes~* Fever of 100.4 degrees Fahrenheit or higher~* Any patient having received a therapeutic cerclage during the current pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): emergent cerclage with no peri-operative antibiotics or indomethacin
- indomethacin and antibiotics (Type: EXPERIMENTAL): perioperative antibiotics and indomethacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with type 2 diabetes on stable doses of background medicines for management of diabetes; aged 18-70 years; body mass index between 22.5 and 45.5 kg/m2~Exclusion Criteria:~Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for PF-04991532 and Sitagliptin
- 150 mg PF-04991532 (Type: EXPERIMENTAL): None
- 450 mg PF-04991532 (Type: EXPERIMENTAL): None
- 750 mg PF-04991532 (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of TAP Block on Postsurgical Pain After Minimally Invasive Partial Nephrectomy:

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* asa score I,II,II~* patients scheduled for robot assisted partial nephrectomy~Exclusion Criteria:~* previous abdominal surgery~* inability to provide informed consent~* allergy to the anesthetic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tap Block (Type: ACTIVE_COMPARATOR): the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
- No Tap Block (Type: ACTIVE_COMPARATOR): the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, \>40 years of age~2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior~3. Spontaneous amenorrhea for at least 12 consecutive months~4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause~5. Bilateral salpingo-oophorectomy \>6 weeks with or without hysterectomy~Exclusion Criteria:~1. BMI ≥ 40 kg/m²~2. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS~3. History of self-injurious behavior~4. History of clinical diagnosis of depression; or treatment for depression~5. History of clinical diagnosis of borderline personality disorder~6. Use of an investigational study medication within 30 days prior to screening or during the study~7. Concurrent participation in another clinical trial or previous participation in this trial~8. Family of investigational-site staff

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brisdelle (paroxetine mesylate) (Type: EXPERIMENTAL): Brisdelle (paroxetine mesylate)
- Placebo capsules (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patient having a diagnosis of HIV-1 infection.~2. Antiretroviral therapy started at least 12 months before, always with a HAART combination including 2 NRTIs plus a PI.~3. Maintained undetectable plasma HIV-1 RNA (VL \< 50 copies/mL) since the beginning of antiretroviral therapy, for at least 6 months.~4. Absence of suspected or documented resistance mutations in the RT associated to NNRTIs or to any NRTI.~5. Patient having at least one of the following conditions:~   * Dyslipemia (LDL cholesterol \>130 mg/dL or triglycerides \> 350 mg/dL) derived from their current PI regimen or current use of lipid-lowering agents due to dyslipemia,~  * Antiretroviral-related gastrointestinal disturbances, or~  * Low patient's satisfaction associated with the current regimen posology (BID regimen, ritonavir use, ritonavir intolerance...).~6. Good treatment adherence.~7. Voluntary written informed consent.~Exclusion Criteria:~1. Previous therapy with mono or dual antiretroviral therapies after initial of HAART era.~2. Previous antiretroviral treatment failures, treatment interruptions (A) or blips (B) in viral load (VL \> 50 copies/mL).~3. Acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion.~4. Pregnancy or fertile women willing to be pregnant.~5. Clinically significant malabsorption syndrome within 30 days prior to randomization.~(A) Patients who in the past made any interruption of treatment (provide that it has not been in the last year) may be considered candidates for the study, if they meet other criteria for inclusion, since the break in the treatment should not assume the emergence of mutations.~(B) Small blips that are preceded or forwarded by 2 undetectable viral loads will not be taken in care.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Etravirine group (Type: EXPERIMENTAL): To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
- Control group (Type: ACTIVE_COMPARATOR): Continue with the same antiretroviral regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* English speaking~* DSM5 diagnosis of opioid use disorder~* Receiving buprenorphine or methadone for treatment of opioid use disorder~* Agreeable to abstaining from using any cannabis or CBD products for the duration of the trial.~Exclusion Criteria:~* Any self-reported use of cannabis or CBD products in the past 30 days~* Baseline depression (PHQ9) or anxiety (GAD7) scores of greater than 10~* Currently pregnant~* Hepatic liver enzymes greater than 3x upper normal limit~* Hypersensitivity to cannabinoids or sesame oil (CBD solution comes in sesame oil emulsion)~* Currently taking any medications with known significant pharmacokinetic interactions with CBD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cannabidiol 600mg (Type: EXPERIMENTAL): All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
- Placebo (Type: PLACEBO_COMPARATOR): All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete